Jiangxi Rimag Group’s stock closed at HK$4.94 on Wednesday, only slightly higher over the past month, yet the new half year numbers tell a rougher story. The company is still pursuing its recovery narrative while booking a net loss of C¥13.9 million in H1 2026 and a trailing twelve month loss of C¥26.6 million. Revenue reached C¥513.0 million for the half, which may keep some growth-focused investors interested. However, the earnings hit reinforces that this is still a loss making healthcare stock rather than a completed turnaround.
Appreciate the revenue traction at Jiangxi Rimag Group, but concerned about the ongoing losses? Consider using our screener of loss-making peers with stronger balance sheets and clearer paths to profitability as a benchmark, starting with list of solid balance sheet and fundamentals stocks (423 results).
Prefer clean visuals instead of another wall of earnings tables and commentary? See Jiangxi Rimag Group’s full financial picture with a simple visual view of its recent losses and revenue trends in the company report for Jiangxi Rimag Group.
For investors focused on the growth angle at Jiangxi Rimag Group, the H1 2026 results still give some support. Revenue reached C¥513.0 million for the half, which aligns with a healthcare and medtech platform that is at least holding investor interest on the top line. The trailing twelve month loss of C¥26.6 million is smaller than the prior C¥33.3 million loss, so the direction of the longer run earnings trend is less negative than the single half year profit to loss swing suggests.
The move from a C¥16.4 million profit in H1 2025 to a C¥13.9 million loss in H1 2026 challenges the recovery story at Jiangxi Rimag Group. Basic EPS flipped from earnings of C¥0.0459 per share to a loss of C¥0.036, which reinforces that the business model is not yet consistently profitable. The 90 day share price decline of 32.0% signals that investors have already reacted to these pressures, even though the trailing twelve month loss has narrowed versus last year.
Compare Jiangxi Rimag Group’s revenue traction with its profit reversal and the 32.0% share price decline by checking whether analysts see a credible recovery or more downside risk. See the consensus price target analysis for Jiangxi Rimag Group to understand how current targets line up with this mixed earnings picture.If Jiangxi Rimag Group’s mix of revenue traction and recent profit reversal has caught your attention, register for free with Simply Wall St and add it to a Watchlist so you can track price against fair value and be ready when the setup looks right. Once you own stocks, use the Portfolio Command Center to cut through noise and focus on the updates that actually matter to your holdings. For a broader view on sentiment and ideas, turn to the Community and see how other investors are thinking about opportunities and risks. By surfacing hidden catalysts and potential red flags early, Simply Wall St helps you act with confidence and stay ahead of the market.
Some stocks are already building quiet breakout momentum while most investors are still focused elsewhere. Explore fresh ideas that are under the radar for now, before the window tightens, and consider your options promptly.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com